Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- Google+
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Media

Corporate Communications

Here you can find a variety of information:

Our Corporate Communications team can be reached at pr-fre@fresenius.com.

“A pharmacy today? We need to expand it or add something new to it.” (Dr. Eduard Fresenius, Founder, 1912)

October 29, 2019 | Bad Homburg, Germany

Conference Call Q3 2019, Fresenius

Import (ICS)

News

Brief News
Fresenius Vamed completes main university hospital building in Kiel

After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Kiel. The completion marks the first milestone in the modernization of Germany’s second-largest university hospital, with the main building of the Lübeck location scheduled to open in November. The project includes new construction and the comprehensive renovation of the two university hospital locations, some 80 kilometers (50 miles) apart in Schleswig-Holstein state, and their technical management through 2044. With a total volume of €1.7 billion, the UKSH’s modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.

August 20, 2019Fresenius Vamed

Brief News
Fresenius Helios expands preventive medicine offering

Fresenius Helios has opened a new Helios Prevention Center in Berlin, as the company continues the expansion of its occupational medicine activities into a standalone business area. The modern, 440-square-meter (4,700-square-foot) center in the heart of Germany’s capital offers comprehensive check-ups from a single source. HCP patients are accompanied throughout the check-up by their own personal physician, and do not have to search for the right department for their next test, deal with different contact persons, or face long waiting times. And if a test turns up something requiring medical treatment, the patient has direct access to the Helios healthcare network and an exclusive hotline for making appointments with specialists.

August 05, 2019Fresenius Helios
Fresenius raises Group sales growth guidance after good second quarter

July 30, 2019Fresenius

Fresenius Medical Care on track to achieve full-year targets after solid second quarter

July 30, 2019Fresenius Medical Care
Fresenius Medical Care celebrates 40th anniversary of Schweinfurt plant, company’s largest for dialysis machines

July 19, 2019Fresenius Medical Care

Fresenius Medical Care sees U.S. plans for changes to kidney disease care as positive reinforcement of company’s strategy

July 10, 2019Fresenius Medical Care
Brief News
Fresenius Medical Care North America invests in innovative medical wearable venture

Fresenius Medical Care North America (FMCNA) has announced an investment in BioIntelliSense, a Denver-based company that is developing a medical grade data services platform for continuous remote health monitoring, predictive analytics and algorithmic clinical insights. FMCNA is committed to bringing its expertise in advanced analytics and artificial intelligence to the development and deployment of this system in cooperation with BioIntelliSense. The aim is to jointly create clinical pathways that can alert clinicians to the need for early intervention, potentially preventing patients from complications and, thus, reducing unnecessary as well as costly hospitalizations. The investment, therefore, supports Fresenius Medical Care’s strategic goal to improve monitoring, interventions and outcomes for patients living with kidney disease and other chronic illnesses in order to increase their quality of life.

July 09, 2019Fresenius Medical Care

Fresenius Medical Care expands clinical research activities

July 03, 2019Fresenius Medical Care
Fresenius Medical Care successfully places USD bonds

June 14, 2019Fresenius Medical Care

Fresenius Medical Care organizes Organ Donation Day

June 06, 2019Fresenius Medical Care
Brief News
S&P upgrades Fresenius to BBB with stable outlook

Standard & Poor’s has revised Fresenius’ corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook. Fresenius is rated investment grade by the three leading rating agencies Standard & Poor’s (BBB/stable), Moody's (Baa3/stable) and Fitch (BBB-/stable).

May 23, 2019Fresenius

S&P upgrades Fresenius Medical Care to BBB with stable outlook

Standard & Poor’s has upgraded Fresenius Medical Care’s corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook.
May 23, 2019Fresenius Medical Care
Annual General Meeting: Fresenius on course for continued growth, 26th straight increase in dividend approved

May 17, 2019Fresenius

Fresenius Medical Care stays on course for growth – Annual General Meeting approves 22nd straight dividend increase

May 16, 2019Fresenius Medical Care
Brief News
Fresenius Kabi launches biosimilar adalimumab IDACIO® in Germany

Fresenius Kabi is launching its first biosimilar in Germany following the European Commission (EC) granting marketing authorization for IDACIO® for all indications of the reference medicine in the areas of rheumatology, gastroenterology and dermatology.

May 03, 2019Fresenius Kabi

Fresenius makes solid start to 2019 and confirms Group guidance

May 02, 2019Fresenius
Fresenius Medical Care with a good start into 2019

May 02, 2019Fresenius Medical Care

Brief News
Fresenius Kabi receives European Commission approval for adalimumab biosimilar IDACIO®

The European Commission (EC) granted Fresenius Kabi the marketing authorization for IDACIO®, an adalimumab biosimilar, for all indications of the reference medicine. With this EC approval, IDACIO® is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

April 03, 2019Fresenius Kabi
Fresenius Medical Care resolves FCPA investigation

March 29, 2019Fresenius Medical Care

Fresenius Medical Care appoints Dr. Frank Maddux as Global Chief Medical Officer

March 20, 2019Fresenius Medical Care
Brief News
Fresenius Helios and Marburger Bund agree on collective labor agreement

Helios Germany and the doctors' union Marburger Bund have agreed on a collective labor agreement for about 5,400 physicians in 34 Helios hospitals. It applies to the hospitals included in the Helios Group collective labor agreement. With effect from 1 January 2019, the base salary will increase by 2.5 percent. A further increase of 2.5 percent will follow on January 1, 2020. Salaries will thus increase by a total of 5 percent. This is in line with Fresenius Group's expectations.

March 19, 2019Fresenius Helios

Brief News
Fresenius Helios holds topping-out ceremony for new hospital building in Wiesbaden

Fresenius Helios held the topping-out ceremony today for the new main building at Helios HSK hospital in the German city of Wiesbaden, near Frankfurt. The seven-story structure, with almost 100,000 square meters (about 1 million square feet) of floor space, is being erected beside the existing clinic. It will have 22 operating rooms, about 1,000 beds, and a design that significantly reduces distances and waiting times for patients. Helios is investing about €200 million in the new building, while the state of Hesse is contributing €68 million. Completion is scheduled for 2021.

March 15, 2019Fresenius Helios
Fresenius Medical Care completes acquisition of NxStage Medical

February 26, 2019Fresenius Medical Care

Potentialpark study for 2019 finds Fresenius has Germany’s best online offering for job applicants

February 21, 2019Fresenius
Fresenius reports 15th consecutive record year – Significant investments in FY/18 and FY/19 for future growth

February 20, 2019Fresenius

Fresenius Medical Care achieves revised 2018 targets and accelerates investments for future growth

February 20, 2019Fresenius Medical Care
Fresenius Medical Care announces retirement of Chief Financial Officer Michael Brosnan

February 20, 2019Fresenius Medical Care

Brief News
Fresenius Kabi receives positive CHMP opinion for MSB11022, a biosimilar candidate of adalimumab

Fresenius Kabi announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022 a biosimilar candidate of Humira^® (adalimumab)*. The European Commission (EC) will now decide on the approval of MSB11022 which is expected in Q2/ 2019.
*Humira^® is a registered trademark of AbbVie Biotechnology Ltd.

February 01, 2019Fresenius Kabi
Fresenius Medical Care and NxStage extend merger end-date due to government shutdown

January 29, 2019Fresenius Medical Care

Fresenius Medical Care launches 4008A dialysis machine tailored to needs in emerging markets

January 18, 2019Fresenius Medical Care

Disclaimer All news

Order Service News

Would you like to be included on our distribution list for media information? We would be happy to provide you with our latest press releases and brief news by e-mail. This service is free of charge and may be cancelled at any time.

Business & Finance

Medicine & Research

Brief News

German English

First name * Please enter your first name.

Last name * Please enter your lastname.

E-Mail Adress * Please enter your email-address.

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contact

Visit us